Advertisement
News
Advertisement

Mr. Ronald L. Chez Filed Amended 13D for RepliGen Corporation

Wed, 06/22/2011 - 7:36am
Bio-Medicine.Org

CHICAGO, June 22, 2011 /PRNewswire/ -- Amended 13D for RepliGen Corporation was filed with the SEC by Mr. Ronald L. Chez, a private investor.

Mr. Ronald L. Chez is the President of Ronald L. Chez, Inc., and a private investor.

RepliGen Corporation is a biopharmaceutical company focused on building an integrated company by developing and marketing innovative drugs that deliver the benefits of protein therapies in the fields of neurology and gastroenterology.  RepliGen has a core competency in the development and manufacturing of biologics products, which is the basis for its bioprocessing business and RepliGen has out-licensed certain biologics intellectual property, which provide ongoing sources of revenue. Corporate headquarters are located at 41 Seyon Street, Waltham, Massachusetts 02453.

Inquiry Contact:

Barry Fischer

(312) 580-2233

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading